

Giorgio Gentile

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7784385/publications.pdf>

Version: 2024-02-01

63
papers

2,278
citations

236612

25
h-index

214527

47
g-index

64
all docs

64
docs citations

64
times ranked

3417
citing authors

#	ARTICLE	IF	CITATIONS
1	Day-Night Dip and Early-Morning Surge in Blood Pressure in Hypertension. <i>Hypertension</i> , 2012, 60, 34-42.	1.3	264
2	Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients. <i>Journal of Hypertension</i> , 2011, 29, 1253-1269.	0.3	235
3	Prevalence and Correlates of Self-Reported Sexual Dysfunction in CKD: A Meta-analysis of Observational Studies. <i>American Journal of Kidney Diseases</i> , 2010, 56, 670-685.	2.1	155
4	Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. <i>Journal of Hypertension</i> , 2008, 26, 1282-1289.	0.3	121
5	Prevalence and severity of oral disease in adults with chronic kidney disease: a systematic review of observational studies. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 364-375.	0.4	106
6	Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2827-2847.	0.4	94
7	Sexual Dysfunction in Women with ESRD Requiring Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 974-981.	2.2	82
8	Why Is Out-of-Office Blood Pressure Measurement Needed?. <i>Hypertension</i> , 2009, 54, 181-187.	1.3	77
9	The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 971-981.	1.0	76
10	More Versus Less Intensive Blood Pressure—Lowering Strategy. <i>Hypertension</i> , 2016, 68, 642-653.	1.3	75
11	Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials. <i>Journal of Hypertension</i> , 2010, 28, 1356-1365.	0.3	69
12	Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. <i>European Heart Journal</i> , 2008, 30, 679-688.	1.0	66
13	Home Blood Pressure Measurements Will Not Replace 24-Hour Ambulatory Blood Pressure Monitoring. <i>Hypertension</i> , 2009, 54, 188-195.	1.3	56
14	Are Diabetes, Hypertension, and Obesity Independent Risk Factors for Endometrial Polyps?. <i>Journal of Minimally Invasive Gynecology</i> , 2009, 16, 157-162.	0.3	49
15	An independent prognostic factor for the development of endometrial polyps in infertile patients. <i>Fertility and Sterility</i> , 2009, 91, e7-e7.	0.5	46
16	The voltage of R wave in lead aVL improves risk stratification in hypertensive patients without ECG left ventricular hypertrophy. <i>Journal of Hypertension</i> , 2009, 27, 1697-1704.	0.3	44
17	Prevalence and correlates of erectile dysfunction in men on chronic haemodialysis: a multinational cross-sectional study. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2479-2488.	0.4	44
18	Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. <i>Vascular Health and Risk Management</i> , 2009, 5, 411.	1.0	39

#	ARTICLE	IF	CITATIONS
19	Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2012, 6, 81-91.	1.0	39
20	New-Onset Hyperglycemia and Acute Coronary Syndrome: A Systematic Overview and Meta-Analysis. <i>Current Diabetes Reviews</i> , 2010, 6, 102-110.	0.6	37
21	β-Blockers Reduce Mortality in Patients Undergoing High-Risk Non-Cardiac Surgery. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 247-259.	1.0	36
22	Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 785-794.	2.2	35
23	Blood Pressure, Proteinuria, and Phosphate as Risk Factors for Progressive Kidney Disease: A Hypothesis. <i>American Journal of Kidney Diseases</i> , 2013, 62, 984-992.	2.1	34
24	Novel Biomarkers for Renal Diseases? None for the Moment (but One). <i>Journal of Biomolecular Screening</i> , 2016, 21, 655-670.	2.6	33
25	Thiamine deficiency and beriberi features in a patient with hyperemesis gravidarum. <i>Nutrition</i> , 2005, 21, 967-968.	1.1	27
26	Is Kt/V useful in elderly dialysis patients? Pro and Con arguments. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 742-750.	0.4	26
27	Aliskiren versus ramipril in hypertension. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010, 4, 193-200.	1.0	23
28	Telmisartan for the reduction of cardiovascular morbidity and mortality. <i>Expert Review of Clinical Pharmacology</i> , 2011, 4, 151-161.	1.3	21
29	Tight Blood Pressure Control in Diabetes: Evidence-Based Review of Treatment Targets in Patients with Diabetes. <i>Current Cardiology Reports</i> , 2012, 14, 89-96.	1.3	21
30	Dual Renin-Angiotensin System Blockade for Nephroprotection: Still under Scrutiny. <i>Nephron</i> , 2015, 129, 39-41.	0.9	20
31	European and US guidelines for arterial hypertension: similarities and differences. <i>European Journal of Internal Medicine</i> , 2019, 63, 3-8.	1.0	20
32	Estimated GFR reporting is not sufficient to allow detection of chronic kidney disease in an Italian regional hospital. <i>BMC Nephrology</i> , 2009, 10, 24.	0.8	16
33	Optimal Therapy in Hypertensive Subjects with Diabetes Mellitus. <i>Current Atherosclerosis Reports</i> , 2011, 13, 176-185.	2.0	16
34	Treatment strategies for osteoarthritis patients with pain and hypertension. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2010, 2, 229-240.	1.2	15
35	Novel effective drugs for diabetic kidney disease? or not?. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 571-601.	1.0	15
36	Comparative assessment of angiotensin receptor blockers in different clinical settings. <i>Vascular Health and Risk Management</i> , 2009, 5, 939.	1.0	14

#	ARTICLE	IF	CITATIONS
37	Blood pressure lowering in the oldest old. <i>Journal of Hypertension</i> , 2010, 28, 1373-1376.	0.3	13
38	The 2018 ESC/ESH hypertension guidelines: Should nephrologists always stop at the lower boundary?. <i>Journal of Nephrology</i> , 2018, 31, 621-626.	0.9	13
39	Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 1349-1361.	0.6	12
40	Managing end-stage renal disease in the elderly: state-of-the-art, challenges and opportunities. <i>Aging Health</i> , 2013, 9, 539-552.	0.3	12
41	Pharmacokinetic, pharmacodynamic and clinical evaluation of aliskiren for hypertension treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 115-128.	1.5	10
42	Benefits of more intensive versus less intensive blood pressure control. Updated trial sequential analysis. <i>European Journal of Internal Medicine</i> , 2022, 101, 49-55.	1.0	9
43	β ₂ -blockers and risk of all-cause mortality in non-cardiac surgery. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010, 4, 109-118.	1.0	7
44	Blood pressure lowering in diabetic patients. <i>Journal of Hypertension</i> , 2012, 30, 438-439.	0.3	7
45	Role and prognostic value of individual ambulatory blood pressure components in chronic kidney disease. <i>Journal of Human Hypertension</i> , 2018, 32, 625-632.	1.0	6
46	The Quest to Standardize Hemodialysis Care. <i>Contributions To Nephrology</i> , 2011, 171, 39-49.	1.1	5
47	Pregabalin-induced urticarial rash and neutropenia in a renal transplant recipient: a case report. <i>BMC Nephrology</i> , 2019, 20, 207.	0.8	5
48	Response to Home Blood Pressure Measurements Will or Will Not Replace 24-Hour Ambulatory Blood Pressure Measurement. <i>Hypertension</i> , 2009, 54, .	1.3	4
49	Low-Dose RATG with or without Basiliximab in Renal Transplantation: A Matched-Cohort Observational Study. <i>American Journal of Nephrology</i> , 2015, 41, 16-27.	1.4	4
50	Should we shift toward higher blood pressure targets in patients with chronic kidney disease. <i>Journal of Nephrology</i> , 2011, 24, 673-685.	0.9	4
51	The emerging role of high-density lipoprotein cholesterol in hypertension trials. <i>Journal of Hypertension</i> , 2009, 27, 458-460.	0.3	3
52	Successful treatment of severe COVID-19 pneumonia and hyperinflammatory syndrome with tocilizumab. <i>BMJ Case Reports</i> , 2021, 14, e238210.	0.2	3
53	Tight Blood Pressure Control in Chronic Kidney Disease. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 139.	0.8	3
54	Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and protection from stroke. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 1171-1174.	0.6	2

#	ARTICLE	IF	CITATIONS
55	Clinical Significance of the Blood Pressure Changes from Day to Night. <i>Current Hypertension Reviews</i> , 2011, 7, 13-19.	0.5	2
56	Chronic kidney disease and risk of mortality, cardiovascular events or end-stage renal disease in older patients with hypertension. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 1213-1216.	0.6	2
57	Hair today, gone tomorrow: How personal protective equipment guidance changed doctor's facial hair during the COVID-19 pandemic. <i>Health Science Reports</i> , 2021, 4, e278.	0.6	2
58	Glucose Lowering, Hypoglycemia, and Cardiovascular Disease Risk. <i>Current Cardiovascular Risk Reports</i> , 2010, 4, 159-164.	0.8	1
59	Emerging therapies in the management of hypertensive patients with osteoarthritis. <i>Clinical Investigation</i> , 2011, 1, 125-136.	0.0	1
60	Performance of creatinine- and cystatin C-based formulas to estimate glomerular filtration rate. <i>European Journal of Internal Medicine</i> , 2020, 80, 16-17.	1.0	1
61	Should we prefer different drugs to treat hypertension in older and younger adults? Practical implications of clinical trials: European perspective. , 2008, 118, 513-6.		1
62	Blood pressure lowering in the oldest old: a step toward abandoning arbitrary blood pressure targets. <i>Journal of Hypertension</i> , 2011, 29, 173-175.	0.3	0
63	Response to Is Vascular Morning Blood Pressure Surge in the Elderly Resistant to Antihypertensives and More Risky?. <i>Hypertension</i> , 2012, 60, .	1.3	0